丹参川芎嗪注射液联合阿司匹林治疗老年CHD合并AMI的疗效  

Therapeutic effect of salvia ligustrazine injection combined aspirin on aged CHD patients with AMI

作　　者：侯朝钋[1] 李刘英[1] 王玉珏[1] HOU Chao-po;LI Liu-ying;WANG Yu-jue(Department of Integrated Chinese and Western Medicine,First People′s Hospital of Zigong City,Zigong,Sichuan,643000,China)

机构地区：[1]自贡市第一人民医院中西医结合科,四川自贡643000

出　　处：《心血管康复医学杂志》2021年第4期465-470,共6页Chinese Journal of Cardiovascular Rehabilitation Medicine

摘　　要：目的:研究丹参川芎嗪注射液联合阿司匹林治疗老年冠心病(CHD)合并AMI患者的疗效。方法:我院的100例老年CHD合并AMI患者被随机均分为阿司匹林组与联合治疗组(在阿司匹林组基础上加用丹参川芎嗪注射液),两组均治疗14d。观察比较两组治疗前后血脂水平、血清基质金属蛋白酶(MMP)-9、hsCRP水平、肱动脉内皮依赖性舒张功能(FMD)、LVEF、血浆血小板膜糖蛋白CD62P、CD63水平、最大血小板聚集率(MPAR)及治疗总有效率。结果:联合治疗组治疗总有效率显著高于阿司匹林组(92.00%比76.00%,P=0.029)。治疗后,与阿司匹林组比较,联合治疗组TC[(3.77±0.89)nmol/L比(3.12±0.76)nmol/L]、TG[(1.98±0.21)nmol/L比(1.25±0.16)nmol/L]、LDL-C[(2.02±0.67)nmol/L比(1.43±0.71)nmol/L]、血浆CD62P[(11.23±1.87)比(9.82±0.69)]、CD63[(23.91±1.72)比(17.25±1.21)]水平、血清MMP-9[(146.71±17.22)ng/ml比(120.32±13.18)ng/ml]、hsCRP水平[(2.47±0.81)ng/L比(1.62±0.78)ng/L]、MPAR[(30.16±1.95)%比(22.81±1.72)%]降低更显著,HDL-C水平[(2.19±0.87)nmol/L比(3.23±0.91)nmol/L]、FMD[(7.92±1.42)%比(8.56±1.57)%]、LVEF[(52.79±3.21)%比(54.90±3.48)%]升高更显著(P<0.05或<0.01)。结论:丹参川芎嗪注射液联合阿司匹林可显著降低老年CHD合并AMI患者血脂水平,降低炎性因子水平、降低血小板聚集率,改善心功能,疗效显著。Objective:To study therapeutic effect of salvia ligustrazine injection combined aspirin on aged patients with coronary heart disease(CHD)complicated AMI.Methods:A total of 100 aged CHD patients with AMI were randomly and equally divided into aspirin group and combined treatment group(received salvia ligustrazine injection based on aspirin group),both group were treated for 14d.Levels of blood lipids,serum matrix metalloproteinase(MMP)-9 and hsCRP,fore brachial artery endothelium dependent diastolic-systolic function(FMD),LVEF,plasma levels of platelet membrane glycoprotein CD62P and CD63,maximum platelet aggregation rate(MPAR)and total effective rate were observed and compared between two groups before and after treatment.Results:Total effective rate of combined treatment group was significantly higher than that of aspirin group(92.00%vs.76.00%,P=0.029).After treatment,compared with aspirin group,there were significant reductions in levels of TC[(3.77±0.89)nmol/L vs.(3.12±0.76)nmol/L],TG[(1.98±0.21)nmol/L vs.(1.25±0.16)nmol/L],LDL-C[(2.02±0.67)nmol/L vs.(1.43±0.71)nmol/L],plasma CD62P[(11.23±1.87)vs.(9.82±0.69)],CD63[(23.91±1.72)vs.(17.25±1.21)],serum MMP-9[(146.71±17.22)ng/ml vs.(120.32±13.18)ng/ml]and hsCRP[(2.47±0.81)ng/L vs.(1.62±0.78)ng/L]and MPAR[(30.16±1.95)%vs.(22.81±1.72)%],and significant rise in level of HDL-C[(2.19±0.87)nmol/L vs.(3.23±0.91)nmol/L],FMD[(7.92±1.42)%vs.(8.56±1.57)%]and LVEF[(52.79±3.21)%vs.(54.90±3.48)%]in combined treatment group(P<0.05 or<0.01).Conclusion:Salvia ligustrazine injection combined aspirin can significantly reduce levels of blood lipids,inflammatory factors,platelet aggregation rate,improve cardiac function in aged CHD patients with AMI.It possesses significant therapeutic effect.

关 键 词：冠心病 心肌梗死 阿司匹林 

分 类 号：R541.4[医药卫生—心血管疾病]